HC Wainwright set a $25.00 price objective on Epizyme (NASDAQ:EPZM) in a research note released on Thursday, TipRanks reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently weighed in on the stock. Wedbush reaffirmed an outperform rating and issued a $21.00 price target on shares of Epizyme in a research note on Wednesday. BidaskClub downgraded shares of Epizyme from a buy rating to a hold rating in a research note on Tuesday. Citigroup reaffirmed a buy rating on shares of Epizyme in a research note on Thursday, May 30th. Zacks Investment Research raised shares of Epizyme from a hold rating to a buy rating and set a $14.00 price target on the stock in a research note on Tuesday, April 30th. Finally, Roth Capital reaffirmed a buy rating on shares of Epizyme in a research note on Wednesday, February 27th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $18.90.

Shares of NASDAQ EPZM traded down $0.04 during mid-day trading on Thursday, reaching $11.96. The company had a trading volume of 2,772 shares, compared to its average volume of 863,238. Epizyme has a twelve month low of $5.14 and a twelve month high of $16.10. The company has a current ratio of 12.55, a quick ratio of 12.55 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.09 billion, a PE ratio of -6.96 and a beta of 2.73.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.07. The company had revenue of $7.89 million during the quarter, compared to analyst estimates of $1.13 million. As a group, analysts predict that Epizyme will post -2 EPS for the current year.

Large investors have recently modified their holdings of the stock. Exane Derivatives acquired a new position in shares of Epizyme during the 1st quarter worth about $84,000. Legal & General Group Plc boosted its holdings in shares of Epizyme by 16.9% during the 4th quarter. Legal & General Group Plc now owns 10,060 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 1,455 shares during the period. Principal Financial Group Inc. bought a new stake in shares of Epizyme during the 1st quarter worth about $135,000. Two Sigma Advisers LP bought a new stake in shares of Epizyme during the 4th quarter worth about $76,000. Finally, BNP Paribas Arbitrage SA boosted its holdings in shares of Epizyme by 992.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 13,627 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 12,380 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.

About Epizyme

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

Featured Article: What does relative strength index mean?

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.